Pritelivir is an oral HSV helicase-primase inhibitor indicated in immunocompromised adults for mucocutaneous HSV lesions refractory to acyclovir, valacyclovir, or famciclovir. The FDA approval of pritelivir for this indication was announced on October 9, 2026.
- Mechanism
- Curator reviewed · 4 references
Pritelivir is an HSV helicase-primase inhibitor that is active against both HSV-1 and HSV-2. It prevents de novo synthesis of viral DNA through inhibition of the viral helicase-primase complex. In kinetic analysis of the pUL5-pUL52-6xHis enzyme complex, the IC50 was 30 nM. Pritelivir retains activity against nucleoside analogue-resistant (for example, acyclovir) and foscarnet-resistant HSV strains.
- Primary indication
- Pritelivir is indicated in immunocompromised adults for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir.Curator reviewed · 3 structured indications
- Formula / weight
- C18H18N4O3S2 · 402.49 g/mol (avg)
- Code names
- AIC-316
Resolves to
IVZKZONQVYTCKC-UHFFFAOYSA-NSMILESCN(C(=O)CC1=CC=C(C=C1)C1=CC=CC=N1)C1=NC(C)=C(S1)S(N)(=O)=OWhat you can answer from here — as of October 19, 2026
Which drugs share a target with Pritelivir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account